Epigenetic modulation to overcome immune suppression in pancreatic cancer - PubMed
4 hours ago
- #Pancreatic Cancer
- #Epigenetics
- #Immunotherapy
- Pancreatic ductal adenocarcinoma (PDAC) has a highly fibrotic and immunosuppressive tumor microenvironment (TME).
- Epigenetic dysregulation contributes to immune suppression, stromal remodeling, and immune evasion in PDAC.
- Epigenetic therapies can restore tumor immunogenicity and promote cytotoxic T cell infiltration.
- Combining epigenetic modulators with immune checkpoint blockade shows promise in remodeling the PDAC TME.
- Challenges include poor drug penetration, off-target effects, tumor hypoxia, and adaptive resistance.
- Epigenetic reprogramming may overcome PDAC immunoresistance by reactivating antigen presentation and disrupting immunosuppressive networks.
- Future directions include rational combination regimens, predictive biomarkers, and understanding context-dependent epigenetic regulation.